Communiqués MyMD Pharmaceuticals, Inc. BOERSE MUENCHEN

Actions

DQS0

US62856X2018

Blockchain & Cryptomonnaies

Temps réel BOERSE MUENCHEN Autres places de cotation			Varia. 5j.	Varia. 1 janv.
- ^EUR	-.--%		+2 616,54%	+1 482,57%

15/05	Q/C Technologies, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
15/04	Q/C Technologies, Inc. publie ses résultats pour l'exercice clos le 31 décembre 2025	CI

Communiqués

30/06	Q/C Technologies Relocates Headquarters to San Francisco in Proximity to World-Class Engineering Experts for Photonic Computing and Optical AI Inference Initiative	AQ
18/03	Q/C Technologies Launches Optical Processing Unit (OPU) Initiative to Develop Proprietary Silicon Photonic Computing Architecture for AI Inference	AQ
20/01	Q/C Technologies Appoints AI Systems Leader Chelsea Voss to Board of Directors	AQ
09/12	Quantum-Class Computing Developer Q/C Technologies Welcomes Strategic Advisor Martin Shkreli	AQ
30/10/25	Q/C Technologies Introduces Proprietary qc-LPU100™ Brand of Quantum-Class Laser Processing Units	AQ
16/10/25	Q/C Technologies Appoints Technion Professor Dr. Steven Frankel as Senior Quantum Advisor to Advance Photonic and Quantum-Class Computing Initiatives	AQ
25/09/25	Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol “QCLS”	BU
24/09/25	TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol “QCLS” to Reflect Strategic Focus on Quantum Class Photonic Computing	BU
17/09/25	TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement	BU
08/09/25	TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference	BU
04/09/25	TNF Pharmaceuticals Announces Closing of $7 Million Private Placement	BU
02/09/25	TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications	BU
28/08/25	TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance	BU
19/08/25	TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation	BU
24/06/25	TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease	BU
08/05/25	TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists	BU
22/04/25	TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development	BU
16/04/25	TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025	BU
17/03/25	TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia	BU
05/03/25	TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025	BU
25/02/25	TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor	BU
29/01/25	TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment	BU
15/01/25	TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion	BU
19/12/24	TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs	BU
09/12/24	TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference	BU